Lupin launches generic Tetrabenazine Tablets

Deepthi | Myequity news | Date : 21-11-2018 16:30:00 IST

Pharma major Lupin launched Tetrabenazine Tablets, 12.5 mg and 25 mg having received an approval from the United States Food and Drug Administration (FDA) earlier.

Lupin’s Tetrabenazine Tablets, 12.5 mg and 25 mg are the generic equivalent of Valeant Pharmaceuticals North America, LLC’s Xenazine® tablets. It is indicated for the treatment of chorea associated with Huntington’s disease.

Xenazine® tablets had annual sales of $153 million in the US (IQVIA MAT September 2018).

About Lupin Limited


Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded &generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.


More from Myequity